RecruitingNot ApplicableNCT06713187
Interleukin23 in Systemic Lupus
Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
Sponsor
Sohag University
Enrollment
90 participants
Start Date
May 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria1
- patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.
Exclusion Criteria1
- patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALinterleukin 23
assessment of interleukin 23 in Sera of patients using ELIZA
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06713187